Monday, December 16, 2019
12:01 PM EST – Novoheart Holdings Inc. : A global stem cell biotech company that invented and commercialized the world’s first and only “human heart-in-a-jar” model for drug discovery and development, is pleased to announce an exclusive licensing agreement with Harvard University’s Office of Technology Development. Novoheart Holdings Inc. (V.NVH) shares were up $0.04 at 0.58.
Stocks in Play: Novoheart Holdings Inc. , Mon, 16 Dec 2019 12:12:58 EST